As published in The News & Observer:
Biotechnology company, Grifols, announced Wednesday that it has begun clinical trials for a COVID-19 treatment at its facility in Clayton, North Carolina.
Specifically, Grifols has entered into a partnership with the U.S. Biomedical Advanced Research Development Authority (BARDA) and the Food and Drug Administration (FDA) to harvest plasma — the water-based portion of blood that holds many proteins — from recovering COVID-19 patients and process it into a hyperimmune globulin.
The trials will determine if that hyperimmune globulin, which holds antibodies that fight things like viruses and bacteria, can be used to successfully treat COVID-19, the disease caused by the pandemic coronavirus.
Read more from The News & Observer here.
Grifols’ full March 25 press release, announcing its formal collaboration with the U.S. government to produce the first treatment specifically targeting COVID-19, may be read here.